Abstract: The present invention relates to the use of cardiotrophin-1 (CT-1) for the prevention and/or treatment of acute renal injury, specially of acute kidney injury induced by nephrotoxic agents, such as contrast agents, antibiotics, immunosuppressive agents or antineoplastic agents. The invention is also related to compositions comprising said nephrotoxic agents and cardiotrophin-1.

Abstract: A process for producing an interferon alpha 5 (IFNa5) protein by expression in an IFNa5 producing Escherichia coli host cell, wherein incorporation of an extra methionine residue in the N-terminal end of the polypeptide chain is minimized as well as the generation of its oxidized species is disclosed. The IFNa5 protein can be purified by an efficient process to render a biologically active IFNa5.

Abstract: A method to inhibit the formation of skin tumors at early stages and their subsequent progression to carcinoma in a mammal is described, the method including the topical application to the mammal's skin of a composition that includes a therapeutically effective amount of disitertide, together with pharmaceutically acceptable carriers or diluents.

Abstract: The present invention relates to a cold organ preservation composition for transplantation comprising a cold organ preservation solution and cardiotrophin-1 or a functionally equivalent variant thereof. The invention also relates to methods and kits for the preparation of said composition, the uses thereof for the cold organ protection and/or preservation for transplantation (particularly for kidney, lung and heart) and also to the cold preservation methods and cold-preserved isolated organs by these methods.

Abstract: The present invention relates to the use of compositions comprising a type III interferon and oncostatin M and to the use of said compositions for the treatment and prevention of infectious and neoplastic diseases.

Abstract: A process for producing an interferon alpha 5 (IFNa5) protein by expression in an IFNa5 producing Escherichia coli host cell, wherein incorporation of an extra methionine residue in the N-terminal end of the polypeptide chain is minimized as well as the generation of its oxidised species is disclosed. The IFNa5 protein can be purified by an efficient process to render a biologically active IFNa5.

Abstract: The described peptides possess the capacity to bind to Transforming Growth Factor TGF-?1 (TGF-?1), and are potential inhibitors of the biological activity of TGF-?1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-?1 expression, e.g., liver fibrosis, pulmonary fibrosis, corneal fibrosis and haze.

Abstract: The present invention relates to a complex comprising a TGF-?1 inhibitor peptide and a cyclodextrin or a derivative thereof. A TGF-?1 inhibitor peptide emulsion comprising cetyl PEG/PPG-10/1 dimethicone is also provided. Processes for the preparation of said complex and said TGF-?1 inhibitor peptide emulsion are also described, as well as its use for the manufacture of a medicament for the treatment of a disease or condition mediated by a TGF-?1.

Abstract: A Method for the treatment of skin fibrosis with a peptide that inhibits TGF-?, and suitable compositions for its administration. The method includes in particular, the use of peptide P144, a compound that is a known inhibitor of TGF-?, for the treatment of skin fibrosis by topical application. The method is shown effective in an animal model of bleomycin-induced skin sclerosis, to a reduction both of the skin fibrosis and of the content of soluble collagen, without any signs of systemic toxicity being detected. This shows that P144 is effective for topical application in mammals for treating fibrotic skin diseases and pathological scarring of the skin. For the administration of this peptide, stable compositions are also supplied, with pleasant appearance without being greasy, with good spreading characteristics and with a viscosity that permits it to be processed easily in industrial plant, and which are suitable for administering the peptide to humans.